Keyword: Vertex Pharmaceuticals
Investors in five Big Pharmas want the companies to review whether their compensation plans effectively reward executives who hike prices.
It feels as though we say this every year, but it bears repeating: From CEOs and COOs to division chiefs and venture capital partners, women are taking the lead and making an impact all over the life sciences industry.
Which biotech company does Vertex admire? Hint: It’s one some analysts think the CF drugmaker should bought a long time ago.
The newest stop on the film festival circuit is one with entries that are all about rare diseases.
If you were excited about Tesaro selling, you might want to keep an eye on Incyte next.
Leerink Partners analyst Geoffrey Porges hasn't changed his tune: He still thinks Gilead should buy Vertex to aid its revenue struggles.